Sera Prognostics is a women's health company. Co.'s primary commercial product, the PreTRM test, is a commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during week 18 or 20 of gestation that provides a prediction of the expectant mother's risk of delivering spontaneously before 37 weeks' gestation. Co. is discovering and developing several additional biomarker tests to predict other conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others. The SERA average annual return since 2021 is shown above.
The Average Annual Return on the SERA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SERA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SERA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|